Literature DB >> 9362242

Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations.

E Balcells1, Q C Meng, W H Johnson, S Oparil, L J Dell'Italia.   

Abstract

The current study examined the contributions of angiotensin-converting enzyme (ACE) vs. chymase to angiotensin II (ANG II) generation in membrane preparations from left ventricles of humans, dogs, rabbits, and rats and from total heart of mice. ACE and chymase activity were measured in membrane preparations extracted with low or high detergent (LD and HD, respectively) concentrations. We hypothesized that ACE, which is membrane bound in vivo, would be preferentially localized to the HD preparation, whereas chymase, which is localized to the cytoplasm and cardiac interstitium, would be localized to the LD preparation. In human heart, ACE activity was 16-fold higher in the HD than in the LD preparation, whereas chymase activity was 15-fold higher in the LD than in the HD preparation. Total ANG II formation was greater in human heart [15.8 +/- 3.4 (SE) micromol ANG II x g(-1) x min(-1)] than in dog, rat, rabbit, and mouse hearts (3.90 +/- 0.35, 0.41 +/- 0.02, 0.61 +/- 0.07, and 1.16 +/- 0.08 micromol ANG II x g(-1) x min(-1), respectively, P < 0.05, by analysis of variance). ANG II formation from ACE was higher in mouse heart (1.09 +/- 0.05 micromol ANG II x g(-1) x min(-1), p < 0.001) than in rabbit, human, dog, and rat hearts (0.55 +/- 0.06, 0.34 +/- 0.01, 0.32 +/- 0.06, and 0.31 +/- 0.02 micromol ANG II x g(-1) x min(-1), respectively). In contrast, chymase activity was higher in human heart (15.3 +/- 3.4 micromol ANG II x g(-1) x min(-1)) than in dog, rat, rabbit, and mouse hearts (3.59 +/- 0.29, 0.10 +/- 0.01, 0.06 +/- 0.01, and 0.07 +/- 0.01 micromol ANG II x g(-1) x min(-1), respectively). Our results demonstrate important species differences in the pathways of intracardiac ANG II generation. Chymase predominated over ACE activity in human heart, accounting for extremely high total ANG II formation in human heart compared with dog, rat, rabbit, and mouse hearts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9362242     DOI: 10.1152/ajpheart.1997.273.4.H1769

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  50 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.

Authors:  Niels Holmark Andersen; Carl Erik Mogensen
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

Review 2.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

3.  Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

Review 4.  Interference with the renin-angiotensin system in heart failure.

Authors:  R Schulz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02       Impact factor: 3.000

Review 5.  The renin-angiotensin system and prevention of age-related functional decline: where are we now?

Authors:  Corey B Simon; Brittany Lee-McMullen; Dane Phelan; Janine Gilkes; Christy S Carter; Thomas W Buford
Journal:  Age (Dordr)       Date:  2015-02-09

6.  Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis.

Authors:  Waheed Asghar; Ali Aghazadeh-Habashi; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2017-04-07       Impact factor: 4.473

7.  Differential Expression of the Angiotensin-(1-12)/Chymase Axis in Human Atrial Tissue.

Authors:  Hao Wang; Jasmina Varagic; Sayaka Nagata; Neal D Kon; Sarfaraz Ahmad; Jessica L VonCannon; Kendra N Wright; Xuming Sun; Dwight Deal; Leanne Groban; Carlos M Ferrario
Journal:  J Surg Res       Date:  2020-04-30       Impact factor: 2.192

Review 8.  Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.

Authors:  Sarfaraz Ahmad; Jasmina Varagic; Leanne Groban; Louis J Dell'Italia; Sayaka Nagata; Neal D Kon; Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

Review 9.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

Review 10.  Mast cells in human and experimental cardiometabolic diseases.

Authors:  Guo-Ping Shi; Ilze Bot; Petri T Kovanen
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.